Brief: Zealand Pharma Applies To EMA For Marketing Authorization For Glepaglutide In Short Bowel Syndrome

Zealand Pharma A/S

02/06/2025 06:06

June 2 (Reuters) - Zealand Pharma A/S ZELA.CO:

SUBMITS MARKETING AUTHORIZATION APPLICATION TO EUROPEAN MEDICINES AGENCY FOR GLEPAGLUTIDE IN SHORT BOWEL SYNDROME

IN H2 EXPECTS TO INITIATE EASE-5 TRIAL THAT IS ANTICIPATED TO PROVIDE FURTHER CONFIRMATORY EVIDENCE FOR A REGULATORY SUBMISSION IN THE U.S.

Source text: ID:nGNE5KNcRf

Further company coverage: ZELA.CO

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))